Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BETA TT8

Next Previous
Drug Profile

BETA TT8

Alternative Names: BETA 002; BETA-TT8

Latest Information Update: 21 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of New South Wales
  • Developer Filamon
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen-activated protein kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Wet age-related macular degeneration

Most Recent Events

  • 21 May 2026 Preclinical trials in Neurological disorders in Australia (PO) prior to May 2026 (Filamon pipeline, May 2026)
  • 20 May 2026 Filamon plans first in human trial for Wet age-related macular degeneration in Australia in third quarter of 2026
  • 30 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a pre clinical in Wet age-related macular degeneration released by Filamon

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top